Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan Insists Complex Generics Strategy Is Poised To Deliver

Nov 06 2017

• By Jessica Merrill

Business Balance - A businessman carrying paperwork walking over a tight rope.

Related Content

Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle

Oct 04 2017

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Jun 16 2017

Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants

Nov 01 2017

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

Will FDA GMP Observations Stall Biocon’s Run?

Aug 07 2017

Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There

Jul 14 2017

Mylan Takes Issue With FDA Over 'Major' CRL For Advair Generic

May 11 2017

Teva CEO Schultz Walks Smack Into A Rough Financial Situation

Nov 02 2017

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

GSK plc

AstraZeneca PLC

Sanofi

Allergan plc

Amgen, Inc.

Biocon, Ltd.

Roche Holding AG

Momenta Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Generic Drugs Biosimilars Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window